PT2598172T - Catalisadores nucleofílicos para ligação oxima - Google Patents

Catalisadores nucleofílicos para ligação oxima

Info

Publication number
PT2598172T
PT2598172T PT11741727T PT11741727T PT2598172T PT 2598172 T PT2598172 T PT 2598172T PT 11741727 T PT11741727 T PT 11741727T PT 11741727 T PT11741727 T PT 11741727T PT 2598172 T PT2598172 T PT 2598172T
Authority
PT
Portugal
Prior art keywords
nucleophylic
catalyzers
maximum connection
maximum
connection
Prior art date
Application number
PT11741727T
Other languages
English (en)
Portuguese (pt)
Inventor
Siekmann Juergen
Haider Stefan
Rottensteiner Hanspeter
Ivens Andreas
Turecek Peter
Zoechling Oliver
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of PT2598172T publication Critical patent/PT2598172T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT11741727T 2010-07-30 2011-07-29 Catalisadores nucleofílicos para ligação oxima PT2598172T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36918610P 2010-07-30 2010-07-30

Publications (1)

Publication Number Publication Date
PT2598172T true PT2598172T (pt) 2019-06-25

Family

ID=44629987

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11741727T PT2598172T (pt) 2010-07-30 2011-07-29 Catalisadores nucleofílicos para ligação oxima

Country Status (26)

Country Link
EP (3) EP4023247A1 (https=)
JP (7) JP6325818B2 (https=)
KR (6) KR102172133B1 (https=)
CN (3) CN108079312A (https=)
AR (1) AR082941A1 (https=)
AU (1) AU2011282571C1 (https=)
BR (1) BR112013001611B1 (https=)
CA (1) CA2806684C (https=)
CY (1) CY1121943T1 (https=)
DK (1) DK2598172T3 (https=)
EA (2) EA025738B9 (https=)
ES (1) ES2731626T3 (https=)
HR (1) HRP20190990T1 (https=)
HU (1) HUE043790T2 (https=)
LT (1) LT2598172T (https=)
MX (1) MX346271B (https=)
NZ (1) NZ605972A (https=)
PL (1) PL2598172T3 (https=)
PT (1) PT2598172T (https=)
RS (1) RS58900B1 (https=)
SG (2) SG10201913078SA (https=)
SI (1) SI2598172T1 (https=)
SM (1) SMT201900351T1 (https=)
TR (1) TR201908836T4 (https=)
TW (1) TWI534152B (https=)
WO (1) WO2012016131A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
DK2598172T3 (da) * 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
AU2016335860B2 (en) 2015-10-08 2023-08-10 Nektar Therapeutics Combination of an IL-2Rbeta-selective agonist and a long-acting IL-15 agonist
CA3007364A1 (en) * 2015-12-03 2017-06-08 Baxalta Incorporated Factor viii with extended half-life and reduced ligand-binding properties
JP7618383B2 (ja) * 2016-07-22 2025-01-21 ネクター セラピューティクス オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート
US12036283B2 (en) 2017-05-15 2024-07-16 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
JP2022523301A (ja) 2019-01-23 2022-04-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
WO2022182768A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
WO2025133203A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5574187A (en) * 1994-10-06 1996-11-12 Uniroyal Chemical Company, Inc. Process of preparing para substituted phenylamines
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001258536A1 (en) 2000-05-16 2001-11-26 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1653991A2 (en) 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugates of a polymer and a protein linked by an oxime linking group
CN1863549A (zh) * 2003-08-08 2006-11-15 费森尤斯卡比德国有限公司 通过肟连接基团进行连接的聚合物和蛋白质的缀合物
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101237884B1 (ko) 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
WO2006016168A2 (en) 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CN101535339B (zh) * 2006-09-01 2014-11-12 诺沃-诺迪斯克保健股份有限公司 改性糖蛋白
WO2008025856A2 (en) * 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
EP2201953A4 (en) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD CLEANING DISORDERS
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
CN102497884A (zh) * 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
KR101912335B1 (ko) * 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
EP2461821A4 (en) * 2009-07-31 2013-07-03 Bayer Healthcare Llc MODIFIED POLYPEPTIDES OF FACTOR IX AND USES THEREOF
DK2598172T3 (da) * 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse

Also Published As

Publication number Publication date
NZ605972A (en) 2015-04-24
EP4023247A1 (en) 2022-07-06
JP2021038256A (ja) 2021-03-11
KR101969601B1 (ko) 2019-04-17
DK2598172T3 (da) 2019-07-01
JP7258999B2 (ja) 2023-04-17
KR102269494B1 (ko) 2021-06-25
KR102088852B1 (ko) 2020-03-16
JP6757823B2 (ja) 2020-09-23
CA2806684A1 (en) 2012-02-02
MX2013001261A (es) 2013-03-22
ES2731626T3 (es) 2019-11-18
BR112013001611A8 (pt) 2020-10-27
TR201908836T4 (tr) 2019-07-22
CN103370082A (zh) 2013-10-23
JP2017137358A (ja) 2017-08-10
SG10201913078SA (en) 2020-02-27
JP2019116500A (ja) 2019-07-18
MX346271B (es) 2016-07-08
CN108079311A (zh) 2018-05-29
EP2598172B1 (en) 2019-03-27
SMT201900351T1 (it) 2019-07-11
BR112013001611A2 (pt) 2016-05-17
AR082941A1 (es) 2013-01-23
JP6325818B2 (ja) 2018-05-16
AU2011282571B2 (en) 2015-09-24
TWI534152B (zh) 2016-05-21
KR20130043211A (ko) 2013-04-29
JP2013536180A (ja) 2013-09-19
TW201217393A (en) 2012-05-01
SG187171A1 (en) 2013-02-28
JP7054407B2 (ja) 2022-04-13
KR102172133B1 (ko) 2020-11-02
EA201300190A1 (ru) 2013-07-30
KR20200126008A (ko) 2020-11-05
CY1121943T1 (el) 2020-10-14
LT2598172T (lt) 2019-08-26
RS58900B1 (sr) 2019-08-30
SI2598172T1 (sl) 2019-08-30
EP2598172A1 (en) 2013-06-05
HUE043790T2 (hu) 2019-09-30
EP3505186B1 (en) 2022-01-12
AU2011282571C1 (en) 2018-04-05
EA025738B1 (ru) 2017-01-30
KR20210032542A (ko) 2021-03-24
KR20190040364A (ko) 2019-04-17
KR102325780B1 (ko) 2021-11-12
CN108079312A (zh) 2018-05-29
EA201691292A1 (ru) 2017-08-31
CA2806684C (en) 2020-11-17
KR102229967B1 (ko) 2021-03-19
WO2012016131A1 (en) 2012-02-02
JP2019116501A (ja) 2019-07-18
EP3505186A1 (en) 2019-07-03
BR112013001611B1 (pt) 2022-05-10
JP2015164958A (ja) 2015-09-17
PL2598172T3 (pl) 2019-09-30
KR20210079392A (ko) 2021-06-29
AU2011282571A1 (en) 2013-02-07
HRP20190990T1 (hr) 2019-10-04
KR20200029059A (ko) 2020-03-17
JP2022046676A (ja) 2022-03-23
EA025738B9 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
PT2598172T (pt) Catalisadores nucleofílicos para ligação oxima
BR112013030533A2 (pt) catalisadores
PT2556597T (pt) Estrutura de pré-codificador para pré-codificação mimo
PT2552242E (pt) Resumo
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
EP2609148A4 (en) PHTHALIC ACID-FREE SOFT MAKER
DE112011104226A5 (de) Käfigmutter
FR2958287B1 (fr) Microreacteur
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DK2525907T3 (da) Katalysatorbærer
DE112011101226A5 (de) Linearwegmesssystem
DE112011102080A5 (de) Kupplungszentralausrücker
DE102010038420A8 (de) Reinigungungsvorrichtung
DE102011002623A8 (de) Ventilsteuerzeitversteller
DE112011102711A5 (de) Hydrostataktor
DE102010035554B8 (de) Fußtüröffner
DE102010019119B8 (de) Cuttermesser
BR112013003504A2 (pt) encosto traseiro unitário
ES1072252Y (es) Bandeja para lavaplatos
DE112010005518A5 (de) Dichtungsmanchette
CO6801789A2 (es) N-hetarilmetil pirazolilcarboxamidas
BR112013028495A2 (pt) catalisadores